Table 1.
Clinical characteristics of patients recruited in the study
| Characteristic | Discovery and training phase | P | Validation and blinded testing phase | P | ||
|---|---|---|---|---|---|---|
| non-GVHD (n = 22) | aGVHD (n = 63) | non-GVHD (n = 41) | aGVHD (n = 70) | |||
| Median age (range) | 48.5 (24-72) | 50.5 (19-71) | 49 (19-72) | 58 (19-72) | ||
| Disease (%) | .431 | .833 | ||||
| Malignant* | 19 (86.4%) | 58 (92.1%) | 37 (90.2%) | 64 (91.4%) | ||
| Other† | 3 (13.6%) | 5 (7.90%) | 4 (9.80%) | 6 (8.60%) | ||
| Disease status at HCT‡ (%) | .344 | .588 | ||||
| Low/mediate risk | 12 (54.5%) | 27 (42.9%) | 25 (61.0%) | 39 (55.7%) | ||
| High risk | 10 (45.5%) | 36 (57.1%) | 16 (39.0%) | 31 (44.3%) | ||
| Donor type (%) | .281 | .246 | ||||
| Related | 12 (54.5%) | 26 (41.3%) | 24 (58.5%) | 33 (47.1%) | ||
| Unrelated | 10 (45.5%) | 37 (58.7%) | 17 (41.5%) | 37 (52.9%) | ||
| Regimen type (%) | .149 | .014 | ||||
| Nonmyeloablative | 13 (59.1%) | 26 (41.3%) | 13 (31.7%) | 39 (55.7%) | ||
| Myeloablative | 9 (40.9%) | 37 (58.7%) | 28 (68.3%) | 31 (44.3%) | ||
| Maximum GVHD grade (%) | ||||||
| 1-2 | 42 (66.7%) | 46 (65.7%) | ||||
| ≥3 | 21 (33.3%) | 24 (34.3%) | ||||
| Organ target at GVHD onset (%) | ||||||
| Skin | 23 (36.5%) | 16 (22.9%) | ||||
| Gut | 3 (4.76%) | 13 (18.6%) | ||||
| Liver | 2 (3.17%) | 2 (2.86%) | ||||
| Multiple organs | 35 (55.6%) | 39 (55.7%) | ||||
| GVHD diagnosis day after HCT | ||||||
| Before day 14 | 3 (4.80%) | 4 (5.70%) | ||||
| Between days 14 and 42 | 33 (52.4%) | 21 (30.0%) | ||||
| After day 42 | 27 (42.8%) | 45 (64.3%) | ||||
P values were calculated using a 2-sided χ2 test.
*
Malignant disease included acute myelogenous leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, non-Hodgkin lymphoma, Hodgkin disease, myelodysplastic syndrome, diffuse large B-Cell lymphoma, and multiple myeloma.
†
Other disease, which means nonmalignant disease, included severe aplastic anemia, sickle cell anemia, dyskeratosis congenita, myeloproliferative disorder, and myelofibrosis.
‡
Low and high risk of disease status at BMT is according to CIBMTR guidelines.